# Rewriting the radiation playbook: NSABP B-51 and the rise of pathologic precision

## TL;DR

A new trial shows that some breast cancer patients don't need additional radiation after chemotherapy, changing standard treatment approaches.

## Contribution

The study demonstrates that regional nodal irradiation is unnecessary for patients with nodal clearance after chemotherapy.

## Key findings

- Patients with nodal clearance after neoadjuvant chemotherapy do not benefit from regional nodal irradiation.
- The findings support de-escalation of radiation therapy in specific breast cancer cases.
- The results raise questions about immunologic mechanisms and variations among clinical subgroups.

## Abstract

The NSABP B-51/RTOG 1304 trial represents a paradigm shift in breast cancer management, showing that patients achieving nodal clearance after neoadjuvant chemotherapy derive no added benefit from regional nodal irradiation. These results challenge long-standing practice, promotes de-escalation, and raise biologically significant questions, particularly regarding immunologic mechanisms and clinical subgroup variations.